Zeomedix — Department of Defense SBIR Phase II: In this proposal Zeomedix proposes to develop a dressing for infected trauma wounds based

Zeomedix — SBIR Phase II award from Department of Defense.

Amount
$780,029
Agency
Department of Defense · Army
Program / Phase
SBIR · Phase II
Solicitation
2010.3
NAICS
Place of performance
PA
Period
2011-12-29 → 2014-09-30

Description

In this proposal Zeomedix proposes to develop a dressing for infected trauma wounds based on its zeolite encapsulating nitric oxide (NO) technology. Nitric oxide has been shown to enhance the wound healing process as well as act as a powerful antibacterial agent. However, delivery of nitric oxide to a wound area is extremely challenging because NO is a gas. Zeomedixs approach is to use zeolites that bind NO molecules when exposed to a stream of gaseous NO. When NO-loaded zeolites come in contact with water (or wound fluid), NO is released into the wound area. The overall goal of Zeomedixs Phase II project is to develop an optimal NO-zeolite wound dressing for treating infected acute wounds. Our technical approach can be organized into three steps: (1) Develop three different NO-zeolite wound dressing prototypes, consisting of NO-zeolite ointment enclosed within a semi-porous pouch, each having distinct nitric oxide release rates. (2) Characterize the storage stability, cytotoxicity, and antimicrobial efficacy of the prototypes against both planktonic microorganisms and bacterial biofilms in vitro. (3) Evaluate the ability of the two leading prototypes to reduce wound infection and improve wound healing in vivo using a full-thickness infected porcine wound model. The overall goal of Zeomedixf"ff3/4s Phase II project is to develop an optimal NO-zeolite wound dressing for treating infected acute wounds. Our technical approach can be organized into three steps: (1) Develop three different NO-zeolite wound dressing prototypes, consisting of NO-zeolite ointment enclosed within a semi-porous pouch, each having distinct nitric oxide release rates (2) Characterize the storage stability, cytotoxicity, and antimicrobial efficacy of the prototypes against both planktonic microorganisms and bacterial biofilms in vitro (3) Evaluate the ability of the two leading prototypes to reduce wound infection and improve wound healing in vivo using a full-thickness infected porcine wound model